share_log

Veeva Systems | 8-K: Veeva Announces Fiscal 2025 Third Quarter Results

Veeva Systems | 8-K: Veeva Announces Fiscal 2025 Third Quarter Results

Veeva Systems | 8-K：Veeva公佈2025財年第三季度業績
美股SEC公告 ·  2024/12/06 05:15

Moomoo AI 已提取核心訊息

Veeva Systems delivered strong Q3 FY2025 results with total revenues reaching $699.2M, up 13% YoY, driven by subscription services revenue growth of 17% to $580.9M. Operating income increased 41% to $181.4M, while non-GAAP operating income rose 30% to $304.0M. Net income grew 37% to $185.8M, with non-GAAP net income up 32% to $288.3M.The company made significant progress in CRM innovation, with over 30 customers now live on Vault CRM and seven migrations from Veeva CRM to Vault CRM on track for completion by year-end. A fourth top 20 biopharma committed to Vault CRM in November. Additionally, Veeva announced three new AI innovations planned for late 2025, including CRM Bot, Voice Control, and MLR Bot.For Q4 FY2025, Veeva expects revenues between $696-699M and non-GAAP operating income of about $275M. The company updated its FY2025 guidance, projecting total revenues of $2,722-2,725M and non-GAAP operating income of approximately $1,120M.
Veeva Systems delivered strong Q3 FY2025 results with total revenues reaching $699.2M, up 13% YoY, driven by subscription services revenue growth of 17% to $580.9M. Operating income increased 41% to $181.4M, while non-GAAP operating income rose 30% to $304.0M. Net income grew 37% to $185.8M, with non-GAAP net income up 32% to $288.3M.The company made significant progress in CRM innovation, with over 30 customers now live on Vault CRM and seven migrations from Veeva CRM to Vault CRM on track for completion by year-end. A fourth top 20 biopharma committed to Vault CRM in November. Additionally, Veeva announced three new AI innovations planned for late 2025, including CRM Bot, Voice Control, and MLR Bot.For Q4 FY2025, Veeva expects revenues between $696-699M and non-GAAP operating income of about $275M. The company updated its FY2025 guidance, projecting total revenues of $2,722-2,725M and non-GAAP operating income of approximately $1,120M.
Veeva Systems發佈了強勁的2025財年第三季度業績，總營業收入達到$69920萬，同比增長13%，主要受訂閱服務營業收入增長17%至$58090萬的推動。營業收入增長41%至$18140萬，而非公認會計准則營業收入增長30%至$30400萬。凈利潤增長37%至$18580萬，非公認會計准則凈利潤增長32%至$28830萬。該公司在客戶關係管理創新方面取得了顯著進展，目前有超過30個客戶在Vault CRM上使用，同時七個從Veeva CRM遷移到Vault CRM的項目預計將在年底前完成。11月，有一家全球前20的生物製藥公司承諾使用Vault CRM。此外，Veeva還宣佈了三項...展開全部
Veeva Systems發佈了強勁的2025財年第三季度業績，總營業收入達到$69920萬，同比增長13%，主要受訂閱服務營業收入增長17%至$58090萬的推動。營業收入增長41%至$18140萬，而非公認會計准則營業收入增長30%至$30400萬。凈利潤增長37%至$18580萬，非公認會計准則凈利潤增長32%至$28830萬。該公司在客戶關係管理創新方面取得了顯著進展，目前有超過30個客戶在Vault CRM上使用，同時七個從Veeva CRM遷移到Vault CRM的項目預計將在年底前完成。11月，有一家全球前20的生物製藥公司承諾使用Vault CRM。此外，Veeva還宣佈了三項計劃在2025年底推出的新人工智能創新，包括CRM機器人、語音控制和MLR機器人。對於2025財年第四季度，Veeva預計營業收入在$69600萬到$69900萬之間，非公認會計准則營業收入約爲$27500萬。該公司更新了2025財年的指引，預計總營業收入爲$272200萬到$272500萬，非公認會計准則營業收入約爲$112000萬。

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Mangoceuticals
    MGRX
    -- 4.310
    OptimizeRx
    OPRX
    -- 5.280
    MSP Recovery
    MSPR
    -- 2.000
    10x Genomics
    TXG
    -- 10.520
    眾巢醫學
    ZCMD
    -- 1.280
    解鎖完整榜單
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。
    熱門討論
    特斯拉績後巨震，後市你怎麽看？
    特斯拉2024年Q4營收257.1億美元，同比增長2%，不及預期。Cybercab計劃2026年投產，預計車輛業務將於2025年恢復增長。面對特朗普回歸，特斯拉股價能否在2025年繼續攀升？
    TSLA收益預覽：猜測開盤價贏取獎勵！